Avacta Group PLC Total Liabilities
Avacta Group PLC total liabilities. Based on the latest financial reports, Avacta Group PLC (AVCT) has total liabilities worth GBX29.09 Million GBX (≈ $3.54K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AVCT financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Avacta Group PLC (2001–2024)
Total liabilities of Avacta Group PLC from 2001 to 2024. This chart illustrates how Avacta Group PLC's total liabilities have evolved over time, based on quarterly financial data.
Avacta Group PLC Competitors by Total Liabilities
The table below lists competitors of Avacta Group PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dharani Sugars&Chemicals Limited
NSE:DHARSUGAR
|
India | Rs6.68 Billion |
|
amalphi ag
F:AMI
|
Germany | €3.55 Million |
|
Metalex Ventures Ltd.
V:MTX
|
Canada | CA$2.65 Million |
|
Saferoads Holdings Ltd
AU:SRH
|
Australia | AU$4.05 Million |
|
Fuller Smith & Turner
LSE:FSTA
|
UK | GBX292.50 Million |
|
Quest PharmaTech Inc
V:QPT
|
Canada | CA$1.25 Million |
|
Professional Diversity Network Inc
NASDAQ:IPDN
|
USA | $4.18 Million |
|
QcX Gold Corp
V:QCX
|
Canada | CA$132.22K |
Liability Composition Analysis (2001–2024)
This chart breaks down Avacta Group PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AVCT total assets.
Liquidity & Leverage Metrics
Avacta Group PLC Total Liabilities Ratios Explained
Avacta Group PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 202.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avacta Group PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avacta Group PLC (2001–2024)
The table below shows the annual total liabilities of Avacta Group PLC from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX38.99 Million ≈ $4.74K |
-24.13% |
| 2023-12-31 | GBX51.39 Million ≈ $6.25K |
-30.76% |
| 2022-12-31 | GBX74.21 Million ≈ $9.03K |
+1183.93% |
| 2021-12-31 | GBX5.78 Million ≈ $703.26 |
+4.46% |
| 2020-12-31 | GBX5.53 Million ≈ $673.21 |
+112.73% |
| 2019-12-31 | GBX2.60 Million ≈ $316.47 |
+27.50% |
| 2018-07-31 | GBX2.04 Million ≈ $248.21 |
+22.60% |
| 2017-07-31 | GBX1.66 Million ≈ $202.46 |
-1.94% |
| 2016-07-31 | GBX1.70 Million ≈ $206.48 |
-25.24% |
| 2015-07-31 | GBX2.27 Million ≈ $276.19 |
+2.62% |
| 2014-07-31 | GBX2.21 Million ≈ $269.14 |
+5.18% |
| 2013-07-31 | GBX2.10 Million ≈ $255.87 |
+37.27% |
| 2012-07-31 | GBX1.53 Million ≈ $186.40 |
+70.41% |
| 2011-07-31 | GBX899.00K ≈ $109.38 |
-28.19% |
| 2010-07-31 | GBX1.25 Million ≈ $152.33 |
+65.17% |
| 2009-07-31 | GBX758.00K ≈ $92.23 |
+175.64% |
| 2008-07-31 | GBX275.00K ≈ $33.46 |
+27.31% |
| 2007-07-31 | GBX216.00K ≈ $26.28 |
+1036.84% |
| 2006-04-30 | GBX19.00K ≈ $2.31 |
-90.21% |
| 2005-04-30 | GBX194.00K ≈ $23.60 |
-44.25% |
| 2004-04-30 | GBX348.00K ≈ $42.34 |
-15.53% |
| 2003-04-30 | GBX412.00K ≈ $50.13 |
-41.81% |
| 2002-04-30 | GBX708.00K ≈ $86.14 |
+23.13% |
| 2001-04-30 | GBX575.00K ≈ $69.96 |
-- |
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more